Group items tagged

John Goddard, Business Reporter from The Star states "A tax introduced with U.S. health care reforms helps boost Toronto's attractiveness to U.S. medical device manufacturers, says a consultant's report to be released this week.""Toronto's MaRs Centre represents Canada's largest bioscience research cluster, anchored by Sunnybrook Health Research Centre, York University Life Sciences Centre, the University of Toronto and more than two dozen affiliated research institutes."

Robert Lawton Burns focuses on the key role of the 'producers' as the main source of innovation in this wide-ranging analysis of business trends in the manufacturing branch of the health care industry. Written by industry academics and executives, the book provides a detailed overview of the pharmaceutical, biotechnology, genomics/proteomics, medical device and information technology sectors. Most importantly, it describes the growing convergence between these sectors and the need for executives in one sector to increasingly draw upon trends in the others.

Story about Certo-Ex which have a device that streamlines sampling and can revolution the time and money spent by pharmaceutical, environmental and food industries. Mention of how TiEQuest had given them access to network with MaRS.

Story about Certo-Ex which have a device that streamlines sampling and can revolution the time and money spent by pharmaceutical, environmental and food industries. Mention of how TiEQuest had given them access to network with MaRS. Jan 14, 2009

Interest is booming in the use of mobile devices such as Apple's iPhone for image viewing applications. But that excitement may be dampened somewhat with a recent U.S. Food and Drug Administration (FDA) decision to classify an iPhone image viewing application as a class III device requiring premarket approval.

According to PR Newswire "Getinge Canada Limited launched a new audit process for hospitals in Canada to make them aware of the potential to save operational costs when transforming from old to innovative technology used in the Medical Device Reprocessing Department." Gentinge had an exhibit at the MaRS Centre earlier this year.

MaRS Innovation (MI) has signed a co-funding agreement with the Johnson & Johnson Corporate Office of Science and Technology to capitalize and accelerate the use of Toronto-based life-sciences technologies during the early stages of pharmaceutical and medical device development.

"The United States spends more on health care-related research and development than any other country. In 2003, it was estimated that the Federal government alone spent over $26 billion. Pharmaceutical companies, device manufacturers and other private companies invested over $10 billion more. At its best, the American health care system is capable of delivering care unsurpassed anywhere else in the world. Yet, a 1999 Institute of Medicine study estimated that as many as 98,000 Americans die each year from hospital related medical errors. A recent study by the Rand Corporation (a non-profit think tank) concluded that less than 50 percent of encounters with doctors and hospitals resulted in optimal, evidence-based treatment. Studies show that as many as 42 million Americans - almost 15 percent of the population - lack health care insurance. Surveys reveal that patients do not feel they have adequate information about their conditions, and that their experience with health care ranks below that of most other sectors, in fact below that of the post office. In the aggregate, the country is spending nearly $2 trillion on health care, and yet the nation's health care system does not meet acceptable thresholds for safety, quality, access or cost. In 2005, VHA Health Foundation's board of directors sought to better understand the reasons behind this paradox. The foundation commissioned Larry Keeley and his associates at Doblin Inc. to apply the rigorous analytical methods that are used in their evaluation of other American industries and companies. The project set out to discover when, where and how innovation was taking place in health care. It also sought to identify organizations that were developing model innovation processes, and to explore where opportunities for successful innovation might lay."

John Evans spearheads the MaRS project which will help to accelerate commercialization for scientific research. The official launch of the MaRS plan will happen on May 12, 2003.

Toronto's medical community is buzzing about an invention that could change the way health professionals screen for infectious disease and cancer.

Segasist Technologies, a MaRS Discovery District Client, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Prostate Auto-Contouring software 'Segasist P-AC'.

Business News Network speaks to John Aikman, Director Somnaform. Somnaform is the maker of a special pillow to stop sleep apnea, the leading cause of snoring. Sept 25, 2009

Ron Freeman, CEO of Research at InfoSource Inc, says that our current funding model isn't working to commercialize our science. That new policy measures are needed to improve Canada's long-term competitive position.

Grade 12 students from St. Elizabeth Catholic High School won first place prize in the 2009 Sanofi-Aventis BioTalent Challenge (SABC) in the Greater Toronto region. These students' research demonstrated that high frequency ultrasound could be used to test the effectiveness of a cancer therapy drug by detecting cell death in leukemia cells. MaRS is one of the Regional competition sponsors.

Grade 12 students from St. Elizabeth Catholic High School won first place prize in the 2009 Sanofi-Aventis BioTalent Challenge (SABC) in the Greater Toronto region. These students' research demonstrated that high frequency ultrasound could be used to test the effectiveness of a cancer therapy drug by detecting cell death in leukemia cells. MaRS is one of the Regional competition sponsors. April 15, 2009

There is opportunity to grow a significant neurotechnology industry in Ontario. MaRS Discovery District aims to help move promising discoveries out of the lab and into the marketplace.

The week of October 3, 2011,  Segasist Technologies, a MaRS client and tenant will launch its' new cancer diagnostic tool Reconcillio at the American Society for Radiation Oncology conference. Reconcillio is Segasist Technologies' third product and is awaiting FDA approvals.

MaRS clients are featured in the Globe and Mail on the occasion of the announcement of MaRS' addition to the Ontario Network of Excellence (ONE). Clients included in the gallery of technology : Quantum Dental's Canarie System, a non-invasive dental technology; Xagenic, with an advanced STD detection; Sustainable Energy Technologies with their solar technology.